Giddy Up: OSRX Say’s “There’s a new sheriff in town”
The Montana-based pharmacy has achieved 503B status and is gunning to become the top compounder – not just out West – but in all of ophthalmology.
EL SEGUNDO, CALIF. (August 26, 2024) – OSRX®, the Montana-based pharmacy, proudly announces its new status as a 503B outsourcing facility, marking a significant leap toward becoming the top ophthalmic compounder nationwide. Guided by Founder and CEO Anthony Sampietro, OSRX is set to expand its services to allow doctors to bulk order OMNI by OSRX® ophthalmic formulations to their private practices, hospitals, and ambulatory surgery centers.
Sterile compounding in the ophthalmic field is a specialized approach crucial to patient care. OSRX’s 503B status empowers it to manufacture large medication batches, lowering costs, increasing quality assurance, and providing savings to patients. With the growing demand for compounded eyecare medications, OSRX aims to meet the unique needs of each prescriber and their patients by offering bulk ordering to facilities, in addition to patient-specific prescriptions directly to patient homes.
“It’s been a wild ride for our young company,” says Sampietro. “But as a 503B, we can accomplish so much more. Surviving the COVID era and other extraordinary hurdles, we’ve risen to become a profitable, trusted and well-established institution in ophthalmology. And now, our Montana-based operation is uniquely positioned to set a new precedent nationally.”
The FDA-registered 503B will operate from its new 5,300 sq. ft. state-of-the-art facility in Missoula, MT, equipped with cutting-edge technology, ensuring enhanced productivity while maintaining Current Good Manufacturing Practices (cGMP) quality.
“We are applying OSRX’s expertise, talent, and commitment to quality to ensure our 503B business meets CGMP standards and align with the FDA’s requirements for outsourcing facilities,” says Chief Pharmacy Officer Amy Frost, another key leader in this exciting venture for OSRX. “It’s been a challenging, but very rewarding journey. Instead of only being able to ship patient-specific prescriptions, we can now transport in bulk directly to medical facilities. This 503B designation allows us to expand our delivery model to include direct-to-patient and direct-to-facility options – it’s a win-win for prescribers and their patients.”
“Since 2017, our company has been predicated on providing simple, affordable and quality solutions for pre- and post-op care with white-glove treatment,” says Sampietro. “We will continue our long-standing service model. OSRX as a 503B is an expansion of services, not a change. We are not altering what made us who we are.”
OSRX is already licensed as a 503B outsourcing facility in 26 states and anticipates nationwide operation in the coming weeks. Sampietro concludes, “The industry and our competitors have been asking, ‘Who are those guys?’ With the 503B designation, let’s just say OSRX is the new sheriff in town.”
About OSRX:
OSRX is an FDA-registered 503B outsourcing facility committed to transforming ophthalmic care through quality compounded solutions. The Missoula, MT-based company is on a mission to redefine the landscape of the corrective eye care market with a focus on simplicity, affordability and patient-centric care. Trusted by more than 5,500 prescribers across the U.S., OSRX is providing A New View of Medicine®. Learn more at www.osrxpharmaceuticals.com.